Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. - Wikidata - awgldk - TriplyDB

Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.

Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37653125

about

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

P2860

Q38587097-A703C13E-E063-4DDD-BE1C-289E5E597426

P2860

Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37653125

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Incorporating incretin-based t ...... patients with type 2 diabetes.

@en

Incorporating incretin-based t ...... patients with type 2 diabetes.

@nl

type

label

Incorporating incretin-based t ...... patients with type 2 diabetes.

@en

Incorporating incretin-based t ...... patients with type 2 diabetes.

@nl

prefLabel

Incorporating incretin-based t ...... patients with type 2 diabetes.

@en

Incorporating incretin-based t ...... patients with type 2 diabetes.

@nl

P1433

Q37653125-E09AE124-8245-4C12-AC79-674AFDFC1F68

P1476

Q37653125-F416068D-475E-4082-8B8C-755498B9B699

P2093

Q37653125-1432769A-C7DC-44BF-A564-B7A001D14D0B

P2860

Q37653125-012D79E3-747C-41E4-95A6-CA0F081A254D

Q37653125-02608B21-8072-4A43-A4EF-0C0C21B2B634

Q37653125-05273B2C-8655-4327-B8A8-CCD1BD3CACB0

Q37653125-06BCBCC8-D60F-4BC1-8D2D-DC24FCDB4881

Q37653125-11C3E71B-ABAC-4012-979E-1FBCB98C2417

Q37653125-1EF5F443-F35E-4BFA-9561-D4A8F54E8DF2

Q37653125-22A8F47E-9C05-4DC8-BB28-D9F50E86E534

Q37653125-24509AA9-6134-494E-BE58-14F5945A8120

Q37653125-2554DAC6-531F-4415-A7FF-E445B3114372

Q37653125-25F9CD0B-00FE-4F45-A700-5BA0D34C819A

P2888

Q37653125-0EB4F808-A781-467C-B882-77E309CA02DE

P304

Q37653125-F0896AA7-A0F8-4C27-AA88-D82A16A39DC7

P31

Q37653125-664C0C0A-FA33-4304-AC88-6D656CC0EFD8

Q37653125-8CE7A641-8676-4911-BE58-30963A51149C

P356

Q37653125-33F6E87E-4E3B-4818-BBD2-90671F7B1EEB

P407

Q37653125-CF03CBB2-7C92-417D-A6FA-B09C524B120D

P433

Q37653125-E2D3AE9D-5B57-4E44-9103-D99D8E4E8F33

P478

Q37653125-2230DEE2-19C7-4B7C-BB19-11D816E95D4D

P577

Q37653125-22196B85-3849-464F-B518-AD92E3B41F08

Q37653125-99448D3F-D3EF-4FF4-8A0A-E60D22FBC61D

P5875

Q37653125-076239E7-97AC-42E3-9798-BB79E8E0B547

P698

Q37653125-0138C58E-E71F-45BF-9D9E-CABD46FE35B8

P921

Q37653125-099F126F-E8F1-4330-8E53-AE7CAC843923

Q37653125-0B086415-9683-43F1-8F0B-3F2CDC8DEB57

Q37653125-3B7C217C-F0C3-4263-8BCC-008EAA7E5A9D

Q37653125-AA4AB951-993B-4A4C-BECC-20A05203DBC3

Q37653125-F1EC64CB-ECED-4C88-91EA-B88D707B4A19

P932

Q37653125-33F47870-2775-4357-987B-A3AB9E32FBF8

P356

S12325-014-0100-5

P1433

Advances in Therapy

P1476

Incorporating incretin-based t ...... patients with type 2 diabetes.

@en

P2093

Joseph M Tibaldi

http://www.w3.org/2001/XMLSchema#string

P2860

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Evidence based medicine: what it is and what it isn't

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Standards of medical care in diabetes--2013

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

P2888

s12325-014-0100-5

P304

289-317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-014-0100-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260242218

http://www.w3.org/2001/XMLSchema#string

P698

24535623

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

type-2 diabetes

mechanism of action

membrane proteins

maturity-onset diabetes of the young

P932

3961600

http://www.w3.org/2001/XMLSchema#string